Search Results
Exploring therapeutic targets in RA | Dr Gerd Burmester
JAK inhibition in rheumatoid arthritis paradigm shift or just more tools - Gerd Burmester
EULAR 2022: Methotrexate in Current Clinical Practice: Optimizing the Anchor Drug in RA Therapy
Overcoming Challenges in the Management of Refractory Rheumatoid Arthritis
EULAR ANNUAL CONFERENCE OF PARE 2016
Targeted therapies (JAK inhibitors) in Rheumatoid Arthritis : Dr. Indrajit Agrawal
Professor Peter Taylor's NRAS Members Day 2012 Presentation Part 2
Exploring the Role of JAK Inhibitors Across the Spectrum of IMIDs
BEST OF ACR CONVERGENCE 2020 - February 4, 2021
Upadacitinib treating bDMARD-IR PsA & Post-marketing surveillance of tofacitinib treating PsA & RA
What are the JAK Inhibitors
Insights at ACR 2020: Day 3 Beyond RA Highlights
